These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 24750020

  • 1. The role of CD33 as therapeutic target in acute myeloid leukemia.
    Walter RB.
    Expert Opin Ther Targets; 2014 Jul; 18(7):715-8. PubMed ID: 24750020
    [Abstract] [Full Text] [Related]

  • 2. The past and future of CD33 as therapeutic target in acute myeloid leukemia.
    Laszlo GS, Estey EH, Walter RB.
    Blood Rev; 2014 Jul; 28(4):143-53. PubMed ID: 24809231
    [Abstract] [Full Text] [Related]

  • 3. Investigational CD33-targeted therapeutics for acute myeloid leukemia.
    Walter RB.
    Expert Opin Investig Drugs; 2018 Apr; 27(4):339-348. PubMed ID: 29534618
    [Abstract] [Full Text] [Related]

  • 4. CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells.
    Liu Y, Wang S, Schubert ML, Lauk A, Yao H, Blank MF, Cui C, Janssen M, Schmidt C, Göllner S, Kleist C, Zhou F, Rahfeld JU, Sauer T, Schmitt M, Müller-Tidow C.
    Int J Cancer; 2022 Apr 01; 150(7):1141-1155. PubMed ID: 34766343
    [Abstract] [Full Text] [Related]

  • 5. Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia.
    Reusch U, Harrington KH, Gudgeon CJ, Fucek I, Ellwanger K, Weichel M, Knackmuss SH, Zhukovsky EA, Fox JA, Kunkel LA, Guenot J, Walter RB.
    Clin Cancer Res; 2016 Dec 01; 22(23):5829-5838. PubMed ID: 27189165
    [Abstract] [Full Text] [Related]

  • 6. Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here?
    Rashidi A, Walter RB.
    Expert Rev Hematol; 2016 Dec 01; 9(4):335-50. PubMed ID: 26778118
    [Abstract] [Full Text] [Related]

  • 7. CD33-Targeted Therapies: Beating the Disease or Beaten to Death?
    Maakaron JE, Rogosheske J, Long M, Bachanova V, Mims AS.
    J Clin Pharmacol; 2021 Jan 01; 61(1):7-17. PubMed ID: 32875599
    [Abstract] [Full Text] [Related]

  • 8. A dual-targeting approach with anti-IL10R CAR-T cells engineered to release anti-CD33 bispecific antibody in enhancing killing effect on acute myeloid leukemia cells.
    Yan Z, Gu R, Ma H, Chen N, Zhang T, Xu Y, Qiu S, Xing H, Tang K, Tian Z, Rao Q, Wang M, Wang J.
    Cell Oncol (Dordr); 2024 Oct 01; 47(5):1879-1895. PubMed ID: 39008193
    [Abstract] [Full Text] [Related]

  • 9. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct.
    Aigner M, Feulner J, Schaffer S, Kischel R, Kufer P, Schneider K, Henn A, Rattel B, Friedrich M, Baeuerle PA, Mackensen A, Krause SW.
    Leukemia; 2013 Apr 01; 27(5):1107-15. PubMed ID: 23178753
    [Abstract] [Full Text] [Related]

  • 10. In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.
    Minagawa K, Jamil MO, Al-Obaidi M, Pereboeva L, Salzman D, Erba HP, Lamb LS, Bhatia R, Mineishi S, Di Stasi A.
    PLoS One; 2016 Apr 01; 11(12):e0166891. PubMed ID: 27907031
    [Abstract] [Full Text] [Related]

  • 11. CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL.
    Reusing SB, Vallera DA, Manser AR, Vatrin T, Bhatia S, Felices M, Miller JS, Uhrberg M, Babor F.
    Cancer Immunol Immunother; 2021 Dec 01; 70(12):3701-3708. PubMed ID: 34398302
    [Abstract] [Full Text] [Related]

  • 12. Gemtuzumab ozogamicin in acute myeloid leukemia.
    Godwin CD, Gale RP, Walter RB.
    Leukemia; 2017 Sep 01; 31(9):1855-1868. PubMed ID: 28607471
    [Abstract] [Full Text] [Related]

  • 13. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia.
    Kenderian SS, Ruella M, Shestova O, Klichinsky M, Aikawa V, Morrissette JJ, Scholler J, Song D, Porter DL, Carroll M, June CH, Gill S.
    Leukemia; 2015 Aug 01; 29(8):1637-47. PubMed ID: 25721896
    [Abstract] [Full Text] [Related]

  • 14. Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia.
    O'Hear C, Heiber JF, Schubert I, Fey G, Geiger TL.
    Haematologica; 2015 Mar 01; 100(3):336-44. PubMed ID: 25480499
    [Abstract] [Full Text] [Related]

  • 15. Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia.
    Laszlo GS, Harrington KH, Gudgeon CJ, Beddoe ME, Fitzgibbon MP, Ries RE, Lamba JK, McIntosh MW, Meshinchi S, Walter RB.
    Oncotarget; 2016 Jul 12; 7(28):43281-43294. PubMed ID: 27248327
    [Abstract] [Full Text] [Related]

  • 16. Targeting the membrane-proximal C2-set domain of CD33 for improved CD33-directed immunotherapy.
    Godwin CD, Laszlo GS, Fiorenza S, Garling EE, Phi TD, Bates OM, Correnti CE, Hoffstrom BG, Lunn MC, Humbert O, Kiem HP, Turtle CJ, Walter RB.
    Leukemia; 2021 Sep 12; 35(9):2496-2507. PubMed ID: 33589747
    [Abstract] [Full Text] [Related]

  • 17. Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin.
    Cowan AJ, Laszlo GS, Estey EH, Walter RB.
    Front Biosci (Landmark Ed); 2013 Jun 01; 18(4):1311-34. PubMed ID: 23747885
    [Abstract] [Full Text] [Related]

  • 18. CD33 directed bispecific antibodies in acute myeloid leukemia.
    Clark MC, Stein A.
    Best Pract Res Clin Haematol; 2020 Dec 01; 33(4):101224. PubMed ID: 33279180
    [Abstract] [Full Text] [Related]

  • 19. Biting back: BiTE antibodies as a promising therapy for acute myeloid leukemia.
    Walter RB.
    Expert Rev Hematol; 2014 Jun 01; 7(3):317-9. PubMed ID: 24617311
    [Abstract] [Full Text] [Related]

  • 20. An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia.
    Venugopal S, Daver N, Ravandi F.
    Curr Hematol Malig Rep; 2021 Feb 01; 16(1):89-96. PubMed ID: 33630233
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.